Sunil Patel, MD
Internal Medicine · Western Springs, ILNPI 1801987565
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 415 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 17.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,180 and has fallen 89.3% since, to $232 in 2025. Among internal medicine clinicians in IL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 415 payments — averaging $16.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$1K
- GSK$826
- Novo Nordisk$549
- AstraZeneca$470
- Boehringer Ingelheim$438
- Pfizer$427
- plus $3K from 28 others
Across 6 payments — averaging $1448.10 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Adare Pharmaceuticals, Inc.$9K
What the payments were for
- Food & beverage$6,714100%
- Education$210%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 73 | $1,208 |
| GSK | 56 | $826 |
| Novo Nordisk | 36 | $549 |
| AstraZeneca | 26 | $470 |
| Boehringer Ingelheim | 25 | $438 |
| Pfizer | 28 | $427 |
| AbbVie | 17 | $421 |
| Amgen(2 entities) | 16 | $350 |
| Sanofi-aventis U.S. LLC | 21 | $284 |
| Merck | 20 | $274 |
| Novartis | 19 | $273 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 21 | $266 |
| Surmodics, Inc. | 10 | $146 |
| Dynavax Technologies Corporation | 7 | $81 |
| Edwards Lifesciences | 2 | $64 |
| Johnson & Johnson | 5 | $62 |
| Ultragenyx Pharmaceutical Inc. | 3 | $62 |
| Stryker | 2 | $55 |
| Phadia US Inc. | 4 | $53 |
| Boston Scientific | 2 | $49 |
| Bayer | 2 | $47 |
| Corcept Therapeutics | 3 | $43 |
| Alkermes, Inc. | 2 | $36 |
| Abbott | 2 | $35 |
| E.r. Squibb & Sons, L.L.C. | 2 | $31 |
| Amarin Pharma, Inc. | 2 | $28 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $26 |
| Teva Pharmaceuticals USA, Inc. | 1 | $24 |
| Sunovion Pharmaceuticals Inc. | 1 | $23 |
| Philips North America LLC | 1 | $20 |
| Gilead | 1 | $19 |
| Exact Sciences | 1 | $18 |
| Mylan Specialty L.p. | 1 | $17 |
| Hikma Pharmaceuticals USA | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,735 in reported general payments places this provider in the 90th percentile of 5,182 internal medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 39 | $44,148 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $14,206 |
| XareltoRivaroxaban | 13 | $10,911 |
| Breo ElliptaFluticasone/Vilanterol | 18 | $10,742 |
| EntrestoSacubitril/Valsartan | 11 | $7,815 |
| Arnuity ElliptaFluticasone Furoate | 15 | $4,792 |
| Atorvastatin Calcium | 245 | $3,034 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 17 | $2,303 |
| Amlodipine Besylate | 296 | $2,043 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 62 | $1,885 |
| Levothyroxine Sodium | 151 | $1,751 |
| Metoprolol Succinate | 91 | $1,525 |
| Gabapentin | 86 | $1,469 |
| Rosuvastatin Calcium | 101 | $1,370 |
| Pantoprazole Sodium | 65 | $1,085 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $427 | $44,14839 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $826 | $29,73945 claims |
| Johnson & JohnsonXarelto | $62 | $10,91113 claims |
| NovartisEntresto | $273 | $7,81511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,182 internal medicine providers in Illinois.
Other internal medicine in Western Springs
- Zaid JabbarOak Brook$1.2M
- Merle DiamondChicago$1.1M
- David ReckerLibertyville$868K
- Yazen JoudehOrland Park$661K
- Robert KushnerChicago$516K
- William CruikshankOak Lawn$431K
- Romeo UrsuaChicago$420K
- Shaina RozellChicago Ridge$366K
- Kristi Tough DesapriWinnetka$344K
- Peter O DonnellChicago$318K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.